Compare KALA & LOAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KALA | LOAN |
|---|---|---|
| Founded | 2009 | 1989 |
| Country | United States | United States |
| Employees | 6 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.5M | 48.2M |
| IPO Year | 2017 | 1999 |
| Metric | KALA | LOAN |
|---|---|---|
| Price | $2.09 | $4.25 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $31.50 | N/A |
| AVG Volume (30 Days) | ★ 767.7K | 19.0K |
| Earning Date | 04-15-2026 | 04-16-2026 |
| Dividend Yield | N/A | ★ 10.06% |
| EPS Growth | ★ 67.39 | N/A |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | ★ $8,666,307.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $38.36 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.07 | $4.13 |
| 52 Week High | $20.58 | $5.85 |
| Indicator | KALA | LOAN |
|---|---|---|
| Relative Strength Index (RSI) | 53.67 | 48.38 |
| Support Level | $0.18 | $4.14 |
| Resistance Level | $3.96 | $4.48 |
| Average True Range (ATR) | 0.26 | 0.07 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 2.81 | 66.71 |
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.